摘要
Transarterial radioembolization(TARE),derived from transarterial chemoembolization,embolizes tumor blood vessels and elicits tumor brachytherapy by using radionuclide-loaded microspheres,a promising therapeutic modality for locally advanced hepatocellular carcinoma(HCC)[1,2].However,the implementation of TARE in the clinic has been hampered by the lack of efficient radioembolization agents[3,4].
出处
《iLIVER》
2023年第3期177-179,共3页
国际肝胆健康(英文)